These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 24368744)

  • 1. Treatment with D-penicillamine or zinc sulphate affects copper metabolism and improves but not normalizes antioxidant capacity parameters in Wilson disease.
    Gromadzka G; Karpińska A; Przybyłkowski A; Litwin T; Wierzchowska-Ciok A; Dzieżyc K; Chabik G; Członkowska A
    Biometals; 2014 Feb; 27(1):207-15. PubMed ID: 24368744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antioxidant Capacity Is Decreased in Wilson's Disease and Correlates to Liver Function.
    Gromadzka G; Przybyłkowski A; Litwin T; Karpińska A
    Biol Trace Elem Res; 2023 Apr; 201(4):1582-1587. PubMed ID: 35524917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythrocyte metabolism and antioxidant status of patients with Wilson disease with hemolytic anemia.
    Attri S; Sharma N; Jahagirdar S; Thapa BR; Prasad R
    Pediatr Res; 2006 Apr; 59(4 Pt 1):593-7. PubMed ID: 16549536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Wilson disease: an update].
    Seo JK
    Korean J Hepatol; 2006 Sep; 12(3):333-63. PubMed ID: 16998287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap.
    Sinha S; Taly AB
    J Neurol Sci; 2008 Jan; 264(1-2):129-32. PubMed ID: 17765927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zinc treatment prevents lipid peroxidation and increases glutathione availability in Wilson's disease.
    Farinati F; Cardin R; D'inca R; Naccarato R; Sturniolo GC
    J Lab Clin Med; 2003 Jun; 141(6):372-7. PubMed ID: 12819634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutathione improves testicular spermatogenesis through inhibiting oxidative stress, mitochondrial damage, and apoptosis induced by copper deposition in mice with Wilson disease.
    Chen K; Wu L; Liu Q; Tan F; Wang L; Zhao D; Fang X; Liu X; Liu J; Han H
    Biomed Pharmacother; 2023 Feb; 158():114107. PubMed ID: 36502753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wilson disease: histopathological correlations with treatment on follow-up liver biopsies.
    Cope-Yokoyama S; Finegold MJ; Sturniolo GC; Kim K; Mescoli C; Rugge M; Medici V
    World J Gastroenterol; 2010 Mar; 16(12):1487-94. PubMed ID: 20333789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation.
    Bruha R; Marecek Z; Pospisilova L; Nevsimalova S; Vitek L; Martasek P; Nevoral J; Petrtyl J; Urbanek P; Jiraskova A; Ferenci P
    Liver Int; 2011 Jan; 31(1):83-91. PubMed ID: 20958917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compliant treatment with anti-copper agents prevents clinically overt Wilson's disease in pre-symptomatic patients.
    Dzieżyc K; Karliński M; Litwin T; Członkowska A
    Eur J Neurol; 2014 Feb; 21(2):332-7. PubMed ID: 24313946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disturbed copper transport in humans. Part 2: mutations of the ATP7B gene lead to Wilson disease (WD).
    Seidel J; Caca K; Schwab SG; Berr F; Wildenauer DB; Mentzel HJ; Horn N; Kauf E
    Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL149-57. PubMed ID: 11936861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oral zinc in Wilson disease--an alternative to D-penicillamine].
    Ramadori G; Keidl E; Hütteroth T; Dormeyer HH; Manns M; Meyer zum Büschenfelde KH
    Z Gastroenterol; 1985 Jan; 23(1):25-9. PubMed ID: 4060799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case report: Co-occurrence of Wilson disease and oculocutaneous albinism in a Chinese patient.
    Rao R; Shu S; Han YZ; Chiu YJ; Han YS
    Medicine (Baltimore); 2018 Dec; 97(50):e13744. PubMed ID: 30558096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Penicillamine increases free copper and enhances oxidative stress in the brain of toxic milk mice.
    Chen DB; Feng L; Lin XP; Zhang W; Li FR; Liang XL; Li XH
    PLoS One; 2012; 7(5):e37709. PubMed ID: 22629446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of common therapies for Wilson disease: A systematic review and meta-analysis of controlled studies.
    Appenzeller-Herzog C; Mathes T; Heeres MLS; Weiss KH; Houwen RHJ; Ewald H
    Liver Int; 2019 Nov; 39(11):2136-2152. PubMed ID: 31206982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptomatic copper deficiency in three Wilson's disease patients treated with zinc sulphate.
    Dzieżyc K; Litwin T; Sobańska A; Członkowska A
    Neurol Neurochir Pol; 2014; 48(3):214-8. PubMed ID: 24981187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional analysis and drug response to zinc and D-penicillamine in stable ATP7B mutant hepatic cell lines.
    Chandhok G; Horvath J; Aggarwal A; Bhatt M; Zibert A; Schmidt HH
    World J Gastroenterol; 2016 Apr; 22(16):4109-19. PubMed ID: 27122662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased serum antioxidant capacity in patients with Wilson disease is associated with neurological symptoms.
    Bruha R; Vitek L; Marecek Z; Pospisilova L; Nevsimalova S; Martasek P; Petrtyl J; Urbanek P; Jiraskova A; Malikova I; Haluzik M; Ferenci P
    J Inherit Metab Dis; 2012 May; 35(3):541-8. PubMed ID: 22139496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wilson disease - currently used anticopper therapy.
    Członkowska A; Litwin T
    Handb Clin Neurol; 2017; 142():181-191. PubMed ID: 28433101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the Diagnosis and Management of Wilson Disease.
    Roberts EA
    Curr Gastroenterol Rep; 2018 Nov; 20(12):56. PubMed ID: 30397835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.